Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
Saghar Pahlavanneshan, Ali Sayadmanesh, Hamidreza Ebrahimiyan, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-14
Open Access | Times Cited: 72

Showing 51-75 of 72 citing articles:

The role of toll-like receptors (TLRs) and their therapeutic applications in endometrial cancer
Sahereh Arabian, Aynaz Boostan, Satinik Darzi
Clinical & Translational Oncology (2022) Vol. 25, Iss. 4, pp. 859-865
Closed Access | Times Cited: 5
Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers
Xiaofeng Dai, Erik W. Thompson, Kostya Ostrikov
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1880-1880
Open Access | Times Cited: 5
Emerging Targets and Therapeutics in Immuno-Oncology Landscape: Insights from Natural Language Processing Analysis
Kavita A. Iyer, Julian Ivanov, Rumiana Tenchov, et al.
(2023)
Open Access | Times Cited: 2
The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
Irene Veneziani, Claudia Alicata, Lorenzo Moretta, et al.
Biomedicines (2022) Vol. 11, Iss. 1, pp. 64-64
Open Access | Times Cited: 4
Editorial: The role of toll-like receptors and their related signaling pathways in viral infection and inflammation
Oliver Planz, Ralf Kircheis
Frontiers in Immunology (2024) Vol. 15
Open Access
Metadichol an agonist that expresses the entire Toll Like Receptor family in various Cancer Cell Lines and its potential Impact on Cancer Treatment
P.R. Raghavan
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
All-Natural Gelatin-Based Nanoemulsion Loaded with TLR 7/8 Agonist for Efficient Modulation of Macrophage Polarization for Immunotherapy
Ritabrita Goswami, Ahmed Nabawy, Mingdi Jiang, et al.
Nanomaterials (2024) Vol. 14, Iss. 19, pp. 1556-1556
Open Access
Nanomaterial-assisted delivery of CpG oligodeoxynucleotides for boosting cancer immunotherapy
Zhiyu Zhang, Lu Yu, Wenjing Liu, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 184-199
Closed Access
Toll-Like receptor 3 (TLR3) agonists in a multi-peptide vaccine for TFDP3 expressing cancers
Genilda Castro de Omena Neta, Jose Wilson Batista da Silva, Rodger Marcel Lima Rocha, et al.
Research Square (Research Square) (2024)
Open Access
Development and Optimization of a Redox Enzyme-Based Fluorescence Biosensor for the Identification of MsrB1 Inhibitors
Hyun Bo Shim, Hyunjeong Lee, Hwa Yeon Cho, et al.
Antioxidants (2024) Vol. 13, Iss. 11, pp. 1348-1348
Open Access
Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy
Michael Newman
Frontiers in Immunology (2024) Vol. 15
Open Access
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials
Danielle K. DePalo, Ahmad A. Tarhini, Jonathan S. Zager
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 1, pp. 95-104
Closed Access | Times Cited: 3
Novel engineered chimeric engulfment receptors trigger T cell effector functions against SIV-infected CD4+ T cells
Daniel Corey, Françoise Haeseleer, Joe Hou, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 28, pp. 1-10
Open Access | Times Cited: 3
Targeting Toll-Like Receptors in Cancer Immunotherapy
Kiarash Saleki, Nima Rezaei
Springer eBooks (2023), pp. 1-25
Closed Access | Times Cited: 1
Network Pharmacology Combined with GEO Analysis of the Mechanism of Qing-Jin-Hua-Tan Decoction in the Treatment of Non-small Cell Lung Cancer
Yi Wei, Chao Liu
Current Computer - Aided Drug Design (2023) Vol. 20, Iss. 4, pp. 396-404
Closed Access | Times Cited: 1
Pathomorphological Manifestations and the Course of the Cervical Cancer Disease Determined by Variations in the TLR4 Gene
Eglė Žilienė, Arturas Inčiūra, Rasa Ugenskienė, et al.
Diagnostics (2023) Vol. 13, Iss. 12, pp. 1999-1999
Open Access | Times Cited: 1
Novel engineered chimeric engulfment receptors trigger T-cell effector functions against SIV infected CD4+ T cells
Daniel Corey, Françoise Haeseleer, Lawrence Corey
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
TLR2 activates AP-1 to facilitate CTGF transcription and stimulate doxorubicin-induced myocardial injury
Xinyong Cai, Lang Hong, Yuliang Zhan, et al.
Authorea (Authorea) (2023)
Open Access
Reducción de la inmunosupresión inducida por células T reguladoras en leucemia linfoblástica aguda
Paola Nallely Basurto Olvera
(2023)
Open Access
In vitro conditioning of antigen-reactive CD8+ T cells with toll-like receptor agonists enhances their expansion in vivo in an adoptive transfer mouse model
Mohamed L. Salem, Sohaila M. Khalil, Ashraf Sobh, et al.
Research Square (Research Square) (2022)
Open Access
A Combined Adjuvant TF–Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice
Qiao Li, Zhihua Liu, Yi Liu, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1408-1408
Open Access
<i>In Vitro</i> Conditioning of Antigen-Reactive CD8 <sup>+</sup> T Cells with Toll-Like Receptor Agonists Enhances Their Expansion <i>In Vivo</i> in an Adoptive Transfer Mouse Model
Mohamed L. Salem, Sohaila M. Khalil, Ashraf Sobh, et al.
SSRN Electronic Journal (2021)
Closed Access
Previous Page - Page 3

Scroll to top